LUDG - Ludwig Enterprises, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

0.1000

0.0000

(0.00%)

At close: 09:30AM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	0.1000
Open	0.1000
Bid	0.0000 x 0
Ask	0.0000 x 0
Day's Range	0.1000 - 0.1000
52 Week Range	0.0160 - 0.4700
Volume	1,000
Avg. Volume	13,195

Market Cap	34.186M
Beta (5Y Monthly)	2.38
PE Ratio (TTM)	N/A
EPS (TTM)	N/A
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Subscribe to Yahoo Finance Plus to view Fair Value for LUDG

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

ACCESSWIRE
LUDG Files Genomic Patent AI Uncovers Differentially Expressed Genes
Ludwig Enterprises, Inc, (OTC PINK:LUDG) (Ludwig - The Genomics Language Company™) is pleased to announce that recently analyzed genomic mRNA data has revealed differentially expressed genes when comparing tissue from patients with bladder, breast, and colon cancer.
ACCESSWIRE
Ludwig Enterprises to Launch New Nutraceutical in Hair Loss Market
Ludwig Enterprises, Inc, (OTC PINK:LUDG) (Ludwig - The Genomics Language Company™) is planning to expand its direct to consumer and direct to professional sales and marketing strategies to include individuals facing hair loss associated with inflammation.
ACCESSWIRE
Ludwig Enterprises Announces Launch of New Nutraceutical and Strategic Marketing Plan
Ludwig Enterprises, Inc., OTC:LUDG (Ludwig - The Genomics Language Company) has released its strategic sales and marketing plan as it launches its ground-breaking nutraceutical, NuGenea™.
ACCESSWIRE
Ludwig Enterprises Launches NuGenea, Groundbreaking Nutraceutical to Fight Inflammation
Ludwig Enterprises, Inc, (OTC PINK:LUDG) (Ludwig - The Genomics Language Company) is proud to announce that its flagship nutraceutical, NuGenea™ launch will be forthcoming.
ACCESSWIRE
Decoding mRNA for Early Disease Detection, Treatment & Prevention
Ludwig Enterprises, Inc. (OTC PINK:LUDG): Personalized genetic sequencing has taken a front seat in current healthcare attempts to optimize diagnosis and treatment of devastating diseases such as cancer, heart disease and stroke.
ACCESSWIRE
Ludwig Enterprises Announces Agreement with Summit Bancorp to Assist with Cross Listing on the Canadian Stock Exchange
Ludwig Enterprises, Inc. (OTC PINK:LUDG) (Ludwig - The Genomics Language Company ™) is pleased to announce that it has signed an agreement with Summit Bancorp of Ontario Canada to assist them in cross listing on the Canadian Stock Exchange (CSE)."Listing on the CSE expands the number of potential investors that we can attract and partnering with Summit will help Ludwig achieve this objective," says Anne Blackstone Ludwig Enterprises' CEO.
ACCESSWIRE
Ludwig Enterprises Announces Intention to List on the Canadian Stock Exchange
Ludwig Enterprises, Inc., OTC:LUDG, (Ludwig - The Genomics Language Company ™) is pleased to announce it intends in the second quarter of 2023 to file a Non-Offering Prospectus to enable the Company to be listed on the Canadian Stock Exchange (CSE).
ACCESSWIRE
Ludwig Enterprises Developing New Partnerships to Fuel Growth
Ludwig Enterprises, Inc. (Ludwig - The Genomics Language Company ™) is in discussions with several organizations that should contribute significantly to the company's revenue growth. The Ludwig team has entered into discussions with a foreign developer of nutraceutical products to sell their products in the United States.
ACCESSWIRE
Ludwig Enterprise mRNA Program Generating Broad Clinical Interest
Ludwig Enterprises, Inc. (Ludwig - The Genomics Language Company™) and its subsidiary Precision Genomics has attracted significant clinical interest in its patent pending mRNA Inflammatory Index™ which measures inflammatory biomarkers that are associated with chronic diseases such as cancer, diabetes and heart disease.
ACCESSWIRE
Ludwig Enterprises Announces Brand Name for Groundbreaking Nutraceutical
Ludwig Enterprises, Inc. (OTC PINK:LUDG), Ludwig -The Genomics Language Company™ and its subsidiary mRNAforLife, Inc. is pleased to announce the brand name for its, soon to be launched, nutraceutical that has been formulated to reduce chronic inflammation.
ACCESSWIRE
Ludwig Enterprises Develops Program to Support Ketamine Clinics
Ludwig Enterprises, Inc, (OTC PINK:LUDG), The Genomics Language Company™ is pleased to announce an agreement with Drs. Kim Farahay and Jeff Lee to provide them with the Company's newly developed program for use of the mRNA Inflammatory Index™ in Ketamine treatment of patients with Treatment Resistant Depression. Drs.
ACCESSWIRE
New Scientific Evidence Suggests How Chronic Illnesses May Be Prevented
"Chronic inflammation is a silent disorder." Writes Dr. Marvin S. Hausman MD in his white paper Inflammation: A Unifying Causation of Disease - Nutritional Intervention. "All people are being bombarded daily with chronic inflammation which is slowly waging a war of attrition on our tissues and organs. Picture air and water pollution, ionizing radiation from the sun, smoking, automobile emissions, etc.
ACCESSWIRE
Ludwig Enterprises Launches Growth Plan
Ludwig Enterprises, developers of the Inflammatory Index (Patent Pending) and owners of the mRNA For Life nutritional supplement is pleased to announce that it has entered into an agreement with The Fannon Group, to provide healthcare sales and marketing leadership as they begin marketing their flagship products.
ACCESSWIRE
Ludwig Enterprises, Inc. (OTC: LUDG) Prepares to Trade on the OTCQB Market
(OTC PINK:LUDG) Ludwig Enterprises Inc., "The Genetic Language Company" ™ the parent company of Precision Genomics and mRNA for Life Inc., is pleased to announce that they have begun the application process to be approved to trade on the OTCQB Market. This is a significant step towards achieving the company's goal of up-listing to the NYSE.
ACCESSWIRE
Ludwig Enterprises Receives IRB Approval on Bladder Cancer Study
(OTC PINK:LUDG) Ludwig Enterprises,Inc., with its wholly owned subsidiary, Precision Genomics, Inc., a leading-edge innovator of inflammatory genetic biomarkers to diagnose and manage chronic diseases, is pleased to announce Institutional Review Board (IRB) approval of a study titled "Using Measurements of mRNA and Elisa-based Cytokine/Protein Indices to Evaluate Pre- and Post- Diagnosis and Treatment Response of Patients With Urothelial Carcinoma
ACCESSWIRE
Ludwig Enterprises Releases Annual 2022 Shareholder Letter
(OTC PINK:LUDG) Ludwig Enterprises, Inc., a leading-edge innovator of inflammatory genetic biomarkers to diagnose and manage chronic diseases, is pleased to announce the annual shareholder letter for 2022.
ACCESSWIRE
Ludwig Enterprises Acquires Cutting-Edge Dietary Supplement Formula
(OTC PINK:LUDG) Ludwig Enterprises, Inc., a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to announce the acquisition of a nutraceutical formula from Xikoz, Inc. with a planned product release through MyRNA for Life, Inc. in Q1 of 2023.
ACCESSWIRE
Ludwig Enterprises Announces Progress Towards Planned IPO (S1 Filing)
(OTC PINK:LUDG) Ludwig Enterprises, Inc., a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to announce that the company is planning to file a form S-1 registration statement. The company has engaged the Newlin Law Firm to complete the S1 registration statement.
ACCESSWIRE
Precision Genomics (a Ludwig Company) Revealed Major Medical News at a Sequire Spotlight Interview
(OTC PINK:LUDG) Ludwig Enterprises and Precision Genomics, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, Blog Title: Precision Genomics Announces SEQUIRE Spotlight Featuring Dr. Marvin S.
ACCESSWIRE
Precision Genomics Successfully Attends the LD Micro Conference
(OTC PINK:LUDG) Ludwig Enterprises with Precision Genomics, a wholly-owned subsidiary of Ludwig Enterprises, is pleased to announce our recent attendance at the LD Micro Conference was a success. LD Micro Conference is the premier event where investment banks, family offices, and the world's micro-cap companies meet for a week. The conference was attended for Precision Genomics by Dr. Marvin S. Hausman MD.
ACCESSWIRE
Precision Genomics’ New mRNA Technology May Be a Solution to Help Diagnose and Establish Treatment for Long Covid
(OTC PINK:LUDG) Precision Genomics, a wholly owned division of Ludwig Enterprises, Inc., a leading-edge innovator of genetic inflammatory biomarkers and medical artificial intelligence (AI) to diagnose and manage chronic diseases, is pleased to announce that our new mRNA technology may offer a solution to assist in the diagnosis of and establish treatment protocols for, the current healthcare crisis, Long Covid.
Newsfile
Precision Genomics (a Ludwig Company) Will Break Major Medical News at a Presentation for LD Micro Tuesday, Oct. 25th, 2022
Dr. Hausman will Address How Precision Genomics mRNA technology can be a game changer for Long Covid and other significant chronic diseases. Sparks, Nevada--(Newsfile Corp. - October 24, 2022) - Ludwig Enterprises (OTC PINK: LUDG) and Precision Genomics, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to announce that Dr. Marvin S. Hausman MD, Chairman of the Scientific Advisory Board for Precision Genomics (a Ludwig Company), will
ACCESSWIRE
Ludwig’s Genomic-Based mRNA Inflammatory Index - A Ground-Breaking Technology
(OTC PINK:LUDG)Ludwig Enterprises, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to announce more detail on this crucial technology, cooperative contracts, and current applications.
ACCESSWIRE
Ludwig Files a Patent That Could Be a Major Technology Breakthrough in Healthcare
(OTC PINK:LUDG) Ludwig Enterprises, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to announce that the Company has filed a patent on proprietary technology, the "Ludwig mRNA Inflammatory Index™." The patent covers the application of messenger ribonucleic acid (mRNA) in diagnosing, managing, and evaluating inflammatory disease patient treatment response in heart disease, diabetes, autoimmune
ACCESSWIRE
Ludwig Enterprises and Emerson Urology Associates Plan Bladder Cancer BCG Immunotherapy Study
(OTC PINK:LUDG)Ludwig Enterprises, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to announce that the Company has started discussions with Emerson Urology Associates, Concord, MA regarding initiation of a clinical study to evaluate the response of bladder cancer patients to BCG immunotherapy.